Gilead Sciences will use the AI-based platform of insitro to discover and develop treatments for nonalcoholic steatohepatitis (NASH), the companies said today, through a collaboration that could generate more than $1 billion for the South San Francisco, CA, startup focused on drug development using machine learning and data science tools. The companies have inked a […]